溶血磷脂酰胆碱在肥胖相关代谢性疾病中的研究进展  

Research progress of lysophosphatidylcholines in obesity-related metabolic diseases

作　　者：洪烨 倪艳 傅君芬[1] HONG Ye;NI Yan;FU JunFen(Endocrinology Department,Children’s Hospital,Zhejiang University School of Medicine,National Clinical Research Center for Child Health,Hangzhou 310052,China)

机构地区：[1]浙江大学医学院附属儿童医院内分泌科,国家儿童健康与疾病临床医学研究中心,杭州310052

出　　处：《中国科学:生命科学》2025年第2期282-296,共15页Scientia Sinica(Vitae)

基　　金：国家重点研发计划(批准号:2021YFC2701901);浙江省“尖兵”“领雁”研发攻关计划(批准号:2023C03047);国家自然科学基金(批准号:82370863)资助。

摘　　要：溶血磷脂酰胆碱(lysophosphatidylcholines,LPCs)是人体丰度最高的溶血甘油磷脂,可直接作用于靶蛋白,或转换为其他磷脂,在神经系统和周围代谢器官中发挥重要的生理功能.临床研究表明,肥胖、糖尿病、非酒精性脂肪肝病患者血液中多种LPCs浓度下降,且LPCs浓度与身体测量指标及血液检测指标存在相关性,可有效鉴别肥胖及其相关代谢性疾病,预测疾病严重程度,具有潜在的生物标记物功能.LPCs还具有改善肥胖表型、缓解炎症、抑制脂肪从头合成的作用.本文将系统整理LPCs的基本代谢和生理功能,深入探究LPCs在肥胖相关代谢性疾病中的浓度变化和生物学作用,为肥胖及相关代谢性疾病的诊疗提供新思路.Lysophosphatidylcholines(LPCs)are the most abundant lysophospholipids in humans.LPCs signal target proteins or are metabolized into other phospholipids that play essential physiological roles in the central nervous system and peripheral metabolic organs.Clinical studies have indicated that the concentration of circulating LPCs decreases in patients with obesity,diabetes,and nonalcoholic fatty liver diseases.A correlation was noted between LPC concentration and anthropometric measurements or blood detection indicators,which help distinguish obesity from related metabolic diseases effectively and predict disease severity as potential biomarkers.Additionally,LPCs influence the improvement of obese phenotypes,alleviation of inflammation,and inhibition of de novo lipogenesis.This review has comprehensively presented basic metabolisms and physiological roles of LPCs and explored changes in their concentrations and functions in obesity-related metabolic diseases to develop novel therapeutic and diagnostic methods.

关 键 词：溶血磷脂酰胆碱 脂质代谢 肥胖 肥胖相关代谢性疾病 

分 类 号：R589[医药卫生—内分泌]